AR031073A1 - Una nueva forma cristalina de clorhidrato de 6-hidroxi-3-(4-[2-(piperidin-1-il)etoxi)fenoxi]-2-(4-metoxifenil)benzo(b)tiofeno; formulaciones farmaceuticas que comprenden dicha forma cristalina; procedimiento para preparar la forma cristalina mencionada y la forma cristalina que se obtiene con el pro - Google Patents

Una nueva forma cristalina de clorhidrato de 6-hidroxi-3-(4-[2-(piperidin-1-il)etoxi)fenoxi]-2-(4-metoxifenil)benzo(b)tiofeno; formulaciones farmaceuticas que comprenden dicha forma cristalina; procedimiento para preparar la forma cristalina mencionada y la forma cristalina que se obtiene con el pro

Info

Publication number
AR031073A1
AR031073A1 ARP000103928A ARP000103928A AR031073A1 AR 031073 A1 AR031073 A1 AR 031073A1 AR P000103928 A ARP000103928 A AR P000103928A AR P000103928 A ARP000103928 A AR P000103928A AR 031073 A1 AR031073 A1 AR 031073A1
Authority
AR
Argentina
Prior art keywords
crystal form
piperidin
benzo
cancer
phenoxi
Prior art date
Application number
ARP000103928A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR031073A1 publication Critical patent/AR031073A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP000103928A 1999-07-29 2000-07-28 Una nueva forma cristalina de clorhidrato de 6-hidroxi-3-(4-[2-(piperidin-1-il)etoxi)fenoxi]-2-(4-metoxifenil)benzo(b)tiofeno; formulaciones farmaceuticas que comprenden dicha forma cristalina; procedimiento para preparar la forma cristalina mencionada y la forma cristalina que se obtiene con el pro AR031073A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14628699P 1999-07-29 1999-07-29
US14757099P 1999-08-06 1999-08-06
US14977399P 1999-08-19 1999-08-19

Publications (1)

Publication Number Publication Date
AR031073A1 true AR031073A1 (es) 2003-09-10

Family

ID=27386379

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103928A AR031073A1 (es) 1999-07-29 2000-07-28 Una nueva forma cristalina de clorhidrato de 6-hidroxi-3-(4-[2-(piperidin-1-il)etoxi)fenoxi]-2-(4-metoxifenil)benzo(b)tiofeno; formulaciones farmaceuticas que comprenden dicha forma cristalina; procedimiento para preparar la forma cristalina mencionada y la forma cristalina que se obtiene con el pro

Country Status (44)

Country Link
EP (1) EP1204656A2 (de)
JP (1) JP2001064277A (de)
KR (1) KR100697177B1 (de)
CN (1) CN1138770C (de)
AR (1) AR031073A1 (de)
AT (1) AT502318A1 (de)
AU (1) AU6335600A (de)
BE (1) BE1013411A3 (de)
BR (1) BR0003209A (de)
CA (1) CA2314682A1 (de)
CO (1) CO5180570A1 (de)
CZ (1) CZ299311B6 (de)
DE (1) DE10036854A1 (de)
DK (1) DK200001151A (de)
DZ (1) DZ3060A1 (de)
FI (1) FI20001722L (de)
FR (1) FR2796944B1 (de)
GB (1) GB2352717A (de)
GR (1) GR1004084B (de)
HR (1) HRP20000503B1 (de)
HU (1) HUP0003001A2 (de)
ID (1) ID27078A (de)
IL (1) IL137553A (de)
IT (1) IT1318660B1 (de)
LT (1) LT4790B (de)
LU (1) LU90617B1 (de)
LV (1) LV12623B (de)
MD (1) MD2336G2 (de)
MX (1) MXPA00007461A (de)
MY (1) MY128764A (de)
NL (1) NL1015821C2 (de)
NO (1) NO20003879L (de)
PE (1) PE20010385A1 (de)
PL (1) PL341749A1 (de)
PT (1) PT102502A (de)
RO (1) RO121851B1 (de)
SE (1) SE0002792L (de)
SG (1) SG91296A1 (de)
SI (1) SI20426A (de)
SV (1) SV2002000132A (de)
TR (1) TR200002206A2 (de)
TW (1) TWI276437B (de)
UA (1) UA72885C2 (de)
WO (1) WO2001009116A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208384T3 (es) * 1999-07-29 2004-06-16 Eli Lilly And Company Forma cristalina de clorhidrato de 6 hidroxi-3-(4-(2-(piperidin-1-il)-etoxi)-fenoxi)2--(4-metoxifenil)-benzo(b)tiofeno.
EP1757291A3 (de) * 2000-05-08 2009-07-15 Eli Lilly & Company Stabilisierte Formulierungen von 6-Hydroxy-3-(4-[2-(Piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen und deren Salze
US7122203B2 (en) 2000-05-08 2006-10-17 Eli Lilly And Company Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
NZ521393A (en) * 2000-05-08 2004-08-27 Lilly Co Eli Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL) ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
CZ20031098A3 (cs) * 2000-10-20 2003-08-13 Eli Lilly And Company Nová krystalická forma 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]fenoxy)-2-(4-methoxyfenyl)benzo[b]thiofen hydrochloridu
WO2002042289A2 (en) 2000-11-27 2002-05-30 Eli Lilly And Company Process for preparing 3-aryl-benzo[b]thiophenes
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
EP1773811B1 (de) * 2004-07-22 2010-09-08 Eli Lilly And Company Kristallines variables hydrat von (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridincarbonsäureamid-hemisuccinatsalz

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR003930A1 (es) * 1995-02-28 1998-09-30 Lilly Co Eli Procedimiento para preparar compuestos de 2-fenil-3-fenoxi o feniltio-benzotiofeno y sales farmaceuticamente aceptables, compuestos intermediarios de aplicación exclusiva en dicho procedimiento y metodo para preparar los compuestos intermediarios mencionados
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
ZA9710262B (en) * 1996-11-19 1999-05-13 Lilly Co Eli Process for the synthesis of benzothiophenes
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.

Also Published As

Publication number Publication date
UA72885C2 (uk) 2005-05-16
LV12623A (en) 2001-03-20
FR2796944A1 (fr) 2001-02-02
CO5180570A1 (es) 2002-07-30
CZ20002716A3 (en) 2001-05-16
MXPA00007461A (es) 2004-07-16
FR2796944B1 (fr) 2003-01-31
FI20001722A7 (fi) 2001-01-30
MD2336G2 (ro) 2004-06-30
ITMI20001759A1 (it) 2002-01-28
GR20000100265A (el) 2001-03-30
GB0018641D0 (en) 2000-09-13
KR100697177B1 (ko) 2007-03-21
IL137553A (en) 2005-09-25
BE1013411A3 (fr) 2001-12-04
SI20426A (sl) 2001-06-30
SE0002792L (sv) 2001-01-30
LT4790B (lt) 2001-05-25
WO2001009116A2 (en) 2001-02-08
IE20000605A1 (en) 2001-04-04
MD20000162A (en) 2001-04-30
CN1138770C (zh) 2004-02-18
LU90617B1 (fr) 2001-06-15
DE10036854A1 (de) 2001-03-01
HUP0003001A2 (hu) 2002-04-29
ID27078A (id) 2001-02-22
MY128764A (en) 2007-02-28
LV12623B (en) 2001-07-20
AT502318A1 (de) 2007-02-15
HRP20000503B1 (en) 2008-04-30
WO2001009116A3 (en) 2001-05-17
CA2314682A1 (en) 2001-01-29
NO20003879L (no) 2001-01-30
GR1004084B (el) 2002-12-11
PE20010385A1 (es) 2001-04-06
BR0003209A (pt) 2001-03-20
IL137553A0 (en) 2001-07-24
NO20003879D0 (no) 2000-07-28
TWI276437B (en) 2007-03-21
KR20010049916A (ko) 2001-06-15
CN1288007A (zh) 2001-03-21
RO121851B1 (ro) 2008-06-30
CZ299311B6 (cs) 2008-06-18
MD2336F2 (en) 2003-12-31
SE0002792D0 (sv) 2000-07-28
HU0003001D0 (en) 2000-10-28
HRP20000503A2 (en) 2001-06-30
GB2352717A (en) 2001-02-07
DK200001151A (da) 2001-01-30
FI20001722L (fi) 2001-01-30
NL1015821A1 (nl) 2001-01-30
ITMI20001759A0 (it) 2000-07-28
HK1035370A1 (en) 2001-11-23
PL341749A1 (en) 2001-02-12
SG91296A1 (en) 2002-09-17
TR200002206A2 (tr) 2001-03-21
NL1015821C2 (nl) 2002-01-03
SV2002000132A (es) 2002-06-07
PT102502A (pt) 2001-01-31
JP2001064277A (ja) 2001-03-13
FI20001722A0 (fi) 2000-07-28
DZ3060A1 (fr) 2004-05-22
EP1204656A2 (de) 2002-05-15
AU6335600A (en) 2001-02-19
LT2000076A (lt) 2001-02-26
IT1318660B1 (it) 2003-08-27

Similar Documents

Publication Publication Date Title
AR029176A1 (es) Una nueva forma cristalina del clorhidrato de 6-hidroxi-3-(4-[2-(piperidin-1-il) etoxi] fenoxi)-2-(4-metoxifenil) benzo [b] tiofeno aplicables en la inhibicion, entre otros, de estados patologicos asociados con la reduccion de los niveles plasmaticos de estrogenos y composicion farmaceutica que comp
DE602004006994D1 (en) 3-aryloxy und 3-heteroaryloxy substituierte benzo(b) thiophene als therapeutische wirkstoffe mit pi3k aktivität
MXPA00007461A (es) Una nueva forma cristalina de clorohidrato de 6-hidroxi -3-(4-(2-(piperidin -1-il)etoxi)fenoxi) -2-(4-metoxifenil) benzo (b)tiofeno.
IL158899A0 (en) Pharmaceutical compositions for inhibiting angiogenesis containing oleuropein and derivatives thereof
AR035355A1 (es) Una nueva forma cristalina de clorhidrato de 6-hidroxi-3-(4-(2-(piperidin-1-il)etoxi]fenoxi) -2- (4-metoxifenil) benzo (b) tiofeno
NZ552372A (en) Propane-1,3-dione derivative or its salt
RU2000120574A (ru) НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗ[b]ТИОФЕНА ГИДРОХЛОРИДА
RU2000120575A (ru) НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗ[b]ТИОФЕНА ГИДРОХЛОРИДА
CN109237242A (zh) 一种环境治理用设备固定托架
CN202662540U (zh) 备用保险管盒
CN107082900A (zh) 防菌墙壁开关外壳及其制备工艺
TH51167A (th) รูปผลึกชนิดใหม่ของ 6-ไฮดรอกซิ-3-(4-[2-(พิเพอริดิน-1-อิล) เอธอกซิ] เฟนอกซิ)-2-(4-เมธอกซิเฟนิล)เบนโซ [b]ไธโอฟีน ไฮโดรคลอไรด์

Legal Events

Date Code Title Description
FB Suspension of granting procedure